2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint
- PMID: 33774784
- PMCID: PMC8081679
- DOI: 10.1007/s40520-021-01834-x
2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint
Abstract
Background: Since 2014, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide.
Aim: Based on this document, a Southeast Asia Working Group (SEAWG) wished to see how the new ESCEO algorithm developed in 2019 was perceived by Southeast Asian experts and how it was integrated into their clinical practice.
Methods: A SEAWG was set up between members of the international ESCEO task force and a group of Southeast Asian experts.
Results: Non-pharmacological management should always be combined with pharmacological management. In step 1, symptomatic slow-acting drugs for osteoarthritis are the main background therapy, for which high-quality evidence is available only for the formulations of patented crystalline glucosamine sulfate and chondroitin sulfate. In step 2, oral NSAIDs are a useful option, considering the cardiovascular/renal/gastrointestinal profiles of the individual patient. Intra-articular hyaluronic acid and corticosteroids are a possible alternative to oral NSAIDs, but limited evidence is available. If steps 1 and 2 do not give adequate relief of symptoms, tramadol can be used, but its safety is debated. In general, the indications of the ESCEO algorithm are important in Southeast Asian countries, but the reimbursement criteria of local health systems are an important aspect for adherence to the ESCEO algorithm.
Conclusion: This guidance provides evidence-based and easy-to-follow advice on how to establish a treatment algorithm in knee OA, for practical implementation in clinical practice in Southeast Asian countries.
Keywords: Algorithm; Knee osteoartrhitis; Patented crystalline glucosamine sulfate; Symptomatic slow-acting drugs for osteoarthritis.
Conflict of interest statement
SSY has participated in Advisory Boards for Amgen, Eli Lilly, Mylan, Novartis and Zuellig Pharma and has had conference support from Abbvie, Celltrion, Mylan and Pfizer. HMR has received conference support form Mylan, Pfizer, Eli Lilly and Novartis. She has been in the advisory boards for Johnson & Johnson, Novartis, Mylan, Pfizer and Eli Lilly. JKL has participated in Advisory Board for Amgen, Mylan and Zuellig Pharma and has had conference support from Amgen and Mylan. ESV has participated in Advisory Boards for Amgen, Eli Lilly, Mylan, Novartis, Jansenn and Pfizer. NV has participated in Advisory Boards for Mylan and IBSA. MYN, ES, WSC, SBC, ECP have no potential conflict of interest for this manuscript.
References
-
- Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223. - PubMed
-
- Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323–1330. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
